1. VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis
- Author
-
Philippe Riegel, C. Ronde Oustau, Yves Hansmann, Xavier Argemi, N. Douiri, M. Baldeyrou, Nicolas Meyer, Jean-Marc Strub, Daniel Christmann, Sarah Cianférani, Daniel Keller, K. Meghit, Gilles Prévost, Nicolas Lefebvre, Les Hôpitaux Universitaires de Strasbourg (HUS), Institut de bactériologie, Fédération de Médecine Translationelle de Strasbourg (FMTS), Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires (DSA-IPHC), Institut Pluridisciplinaire Hubert Curien (IPHC), and Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Male ,Phosphonoacetic Acid ,medicine.medical_treatment ,Aucun ,medicine.disease_cause ,Virulence factor ,Methicillin ,Drug Resistance, Multiple, Bacterial ,Prospective Studies ,Staphylococcus hyicus ,ComputingMilieux_MISCELLANEOUS ,Aged, 80 and over ,biology ,Staphylococcus lugdunensis ,General Medicine ,Middle Aged ,Staphylococcal Infections ,Sciences du Vivant [q-bio]/Microbiologie et Parasitologie ,Clumping factor A ,3. Good health ,Erythromycin ,Infectious Diseases ,Staphylococcus aureus ,Female ,Fluoroquinolones ,Microbiology (medical) ,Adult ,DNA, Bacterial ,Virulence Factors ,030106 microbiology ,Virulence ,Microbiology ,03 medical and health sciences ,Fosfomycin ,Vancomycin ,medicine ,[CHIM]Chemical Sciences ,Humans ,Amino Acid Sequence ,Aged ,Protease ,Base Sequence ,Sequence Analysis, DNA ,biology.organism_classification ,030104 developmental biology ,Aminoglycosides ,Metalloproteases ,Staphylococcus ,Fusidic Acid ,Follow-Up Studies - Abstract
Objective Staphylococcus lugdunensis is a coagulase-negative staphylococcus that displays an unusually high virulence rate close to that of Staphylococcus aureus . It also shares phenotypic properties with S. aureus and several studies found putative virulence factors. The objective of the study was to describe the clinical manifestations of S. lugdunensis infections and investigate putative virulence factors. Method We conducted a prospective study from November 2013 to March 2016 at the University Hospital of Strasbourg. Putative virulence factors were investigated by clumping factor detection, screening for proteolytic activity, and sequence analysis using tandem nano-liquid chromatography-mass spectrometry. Results In total, 347 positive samples for S. lugdunensis were collected, of which 129 (37.2%) were from confirmed cases of S. lugdunensis infection. Eighty-one of these 129 patients were included in the study. Bone and prosthetic joints (PJI) were the most frequent sites of infection ( n =28; 34.6%) followed by skin and soft tissues ( n =23; 28.4%). We identified and purified a novel protease secreted by 50 samples (61.7%), most frequently associated with samples from deep infections and PJI ( pr 0.97 and pr 0.91, respectively). Protease peptide sequencing by nano-liquid chromatography-mass spectrometry revealed a novel protease bearing 62.42% identity with ShpI, a metalloprotease secreted by Staphylococcus hyicus . Conclusion This study confirms the pathogenicity of S. lugdunensis , particularly in bone and PJI. We also identified a novel metalloprotease called lugdulysin that may contribute to virulence.
- Published
- 2016